Table 1. Demographics, sputum microbiology and antibiotic therapy of CF patients.

Patient #	Sex	Age (years)	Sputum microbiology	Antibiotic therapy	FEV1 (% predicted)		FVC (% predicted)		WBC (*1000/mm3)		PMN (% of WBC)		CRP (mg/dl)
					Pre- therapy	Post-therapy	Pre- therapy	Post-therapy	Pre- therapy	Post-therapy	Pre- therapy	Post-therapy	Pre- therapy	Post-therapy
1	M	36	S. aureus	Ceftazidim Tobramycin	28.9	37.7	43.3	54.6	10.69	9.41	66	54.7	3.6	1.4
2	M	27	P. aeruginosa (mucoid) A. fumigatus	Ceftazidim Tobramycin	25.7	31.5	37.0	44.9	10.37	6.54	74.8	56.9	9.7	3.2
3	M	30	P. aeruginosa S. apiospermum	Sulfametoxazole/Trimetoprim Azithromycin Tobramycin	17.5	17	37.2	35.6	15.63	15.05	72.7	76.4	23.1	32
4	M	30	N/A	Azitrhomycin Tobramycin	35.8	41.6	52.2	62.5	6.90	8.08	55.5	54.2	3.4	2.8
5	F	11	N/A	Ciprofloxacin Azithromycin	105.7	99.3	114.6	107.7	6.43	4.63	39.9	37.6	1.4	1.9
6	M	16	P. aeruginosa, S. aureus	Ciprofloxacin	78.0	72.4	80.4	77.0	8.66	8.71	57.7	59.1	2,2	1.4
7	M	29	P. aeruginosa, S. aureus, H. influenzae	Meropemen Amikacyin	19.1	17.7	31.4	25.6	9.68	6.79	81.6	62.5	27.6	N/A
8	M	17	P. aeruginosa	Ciprofloxacin Azithromycin	65.4	95.9	84.7	104.1	10.20	8.87	60.1	58.1	24.0	3.2
9	F	29	B. cepacia	Minociclin	20.7	22.6	29.9	32.4	11.87	12.17	60.7	62.3	103.8	73.1
10	M	42	P. aeruginosa	Ciprofloxacin Azithromycin	17.8	19.8	33.9	31.1	8.21	6.94	60.5	62.8	N/A	N/A
11	M	24	N/A	N/A	50.4	67.9	64.9	78.4	4.37	8.33	55.6	70.7	12.1	2.9
12	M	19	P. aeruginosa, S. aureus	Ciprofloxacin	57.0	59.7	79.0	84.0	10.33	9.85	57.1	42.9	14.6	6.3
13	F	16	S. aureus	Minociclin Teicoplanin	32.1	34	40.8	48.3	7.98	9.56	45.0	40.5	13.8	2.5
14	F	39	P. aeruginosa	Amikacin Meropenem Ciprofloxacin Tigecycline	40.1	46.6	52.6	58.9	7.6	7.7	61.7	60.3	5.0	2.0
15	M	28	S. aureus B. cepacia	Ceftazidim Tobramycin	62.8	63.8	N/A	86.5	7.05	12.3	57.1	57.7	3.8	1.4
16	M	21	P. aeruginosa	Ciprofloxacin	92.5	100.0	107.0	109.0	10.29	8.23	64.5	47.4	4.2	N/A

N/A: not available.